Aevi Genomic Medicine — Medgenics — Investor Presentation (November 2014)
43 slides from Aevi Genomic Medicine's investor presentation, Nov 3, 2014
Slide 1: Unlocking the potential of gene therapy for rare and orphan diseases
— Unlocking the potential of gene therapy for patients with rare and orphan diseases November 2014
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results
Slide 3: Investment Highlights
Investment Highlights • Rare and Orphan disease focused company • Proof of concept established with TARGT e x vivo gene therapy platform as evidenced by the positive initial data of ongoing TARGT EPO clinical trial • Multiple commercially attractive orphan indications for TARGT EPO identified; data
Slide 4: Management Team - Proven Track Record
Management Team - Proven Track Record • President, Shire Specialty Pharmaceuticals - Responsible for all aspects of the $2.5 billion business e.g., commercial, R&D, manufacturing, etc. • President, Life Sciences, Safeguard Scientifics – Lead Life Sciences PE team, responsible for both investment and
Slide 5: Medgenics Vision
Medgenics Vision 5 Driven by our commitment to patients we strive to create the premier rare and orphan disease company by: x Developing first - to - market or best - in - class therapies that are transformative to patients suffering from life - altering rare genetic diseases x Having unparalleled u
Slide 6: Medgenics Pipeline
Medgenics Pipeline Product Program Area Preclinical Phase 1/2 Phase 2/3 Status TARGT EPO MDGN - 201 Chronic Renal Diseases and Hematological Disorders Renal Anemia - ESRD Ongoing Hypo - Responders to ESA Initiate Q1 15 Anemic CKD Transplant Initiate H1 15 Peritoneal Dialysis Initiate H1 15 Beta Thal
Slide 7: TARGT (Transduced Autologous Restorative Gene Therapy)
TARGT TM (Transduced Autologous Restorative Gene Therapy) 1. H arvest Micro - Organs from abdominal dermis using the proprietary DermaVac device 2. Transduce fibroblasts in Micro - Organs via ex vivo gene therapy to create TARGT EPO 3. Wash out HDAd vector, measure production and choose TARGT EPO fo
Slide 8: Significant Improvements to Technology Platform
Significant Improvements to Technology Platform 8 • Vector optimization • Culture conditions • Re - implantation technique • Engraftment The entire system was re - engineered to increase and stabilize secretion levels in vivo
Slide 9: TARGT Platform Mimics the Natural System
TARGT Platform Mimics the Natural System • Autologous proteins and peptides • Continuous secretion • Physiologic levels – Avoids supratherapeutic spikes • Precise, individualized dosing • Safe – Simple, well - tolerated procedure – Avoids exposure to viral antigen – Avoids viral DNA integration – In
Slide 10: Phase 1/2 trial in ESRD Patients with Renal Anemia
Phase 1/2 trial in ESRD Patients with Renal Anemia 10
Slide 11: MDGN-201 Trial Design
MDGN - 201 Trial 11 Prospective, Open - label, Dose Escalation study, to evaluate Safety and Efficacy (control of Hb 9 - 11 and < 12 g/ d L ) of TARGT EPO in ESRD patients Study Summary Group Treatment N A Low dose eEPO 18 - 25 IU/kg/day 3 + 3 * B Mid dose eEPO 35 - 45 IU/kg/day 3 + 3 * C High dose
Slide 12: TARGT EPO Patient Profile
TARGT EPO Patient Profile • End Stage Renal Disease (ESRD) patients – CKD patients with renal failure and low baseline eEPO secretion – Hemodialysis patients with inability to regulate body fluid levels • rHuEPO dependent – Require 2 - 3 injections on a weekly basis to maintain hemoglobin in target
Slide 13: Patient One Run-in Period
13 Patient One Run - in Period Supratherapeutic levels of rHuEPO required to maintain hemoglobin levels Days Pre-implantation -25 -20 -15 -10 -5 0 Serum rHuEPO, mIU/ml 0 200 400 600 800 1000 1200 Days Pre-implantation -25 -20 -15 -10 -5 0 Serum Hb, g/dL 8 9 10 11 12 13 Patient Description: Age: 70 S
Slide 14: Patient One Interim Results
14 Patient One Interim Results • 3 Transduced Micro - Organs (TARG T EPO ) implanted • Patient stabilizes after approximately 30 days • Target Hb is reached with approx 100 x lower C MAX than rHuEPO • Patient appears to have the ability to auto regulate Hb levels • *Possible hemoconcentration Five m
Slide 15: Patient Two Interim Results
15 Patient Two Interim Results • 2 Transduced Micro Organs (TARGT EPO ) implanted • Patient displays higher peak eEPO but stabilizes after 45 days • Target Hb is reached with approx 100x lower C MAX than rHuEPO . Three months post implantation renal anemia is well controlled • Patient appears to hav
Slide 16: Patient Three Interim Results
Patient Three Interim Results Two months post implantation renal anemia is well controlled • 1 Transduced Micro - Organ (TARGT EPO ) implanted • O nly patient to receive 1 TMO 16 Days from implantation 0 10 20 30 40 50 Serum eEPO, mIU/ml 0 5 10 15 20 Predicted eEPO baseline 2.4mU/ml Days from implan
Slide 17: Potential Paradigm Shift in Treatment of Renal Anemia
Potential Paradigm Shift in Treatment of Renal Anemia • Duration: – patients are meeting target secretion profile of continuously producing physiologic levels of endogenous EPO sufficient to maintain target Hb • Hemoglobin: – all patients are meeting endpoint of hemoglobin ( 9 - 11 and < 12 g/ dL )
Slide 18: Next Steps for MDGN-201 Trial
Next Steps for MDGN - 201 Trial • Q 4 2014 – Complete enrollment in the low dose arm of trial ( 3 additional patients) • Q 1 2015 – Enroll 6 - patient cohort comparing single dose Depo - Medrol to multi - dose Depo - Medrol 18
Slide 19: TARGT EPO in Renal Anemia
TARGT,,,. in Renal Anemia medgenics
Slide 20: Bulk of Diagnosed CKD Patients in Stage III-V (ESRD)
Bulk of Diagnosed CKD Patients in Stage III - V (ESRD) - 2.0 4.0 6.0 8.0 10.0 12.0 14.0 I II III IV V- ESRD Patients MM Stage US CKD Population 20 - 400 800 1,200 1,600 I II III IV V - ESRD Patients 000’s Stage Diagnosed Population • The US CKD patient population is approximately 26 million • The ma
Slide 21: TARGT EPO in Patients Hypo-Responsive to rHuEPO
TARGT EPO in Patients Hypo - Responsive to rHuEPO 21 • Clinical Rationale: – Continuous physiologic levels of eEPO will stimulate bone marrow more effectively and safely than intermittent IV dosing 1 • Commercial Rationale: – Identified orphan population of high unmet need – Reduction of overall pat
Slide 22: Hypo-Responsive to rHuEPO Patient Flow
Hypo - Responsive to rHuEPO Patient Flow 22 600 K ESRD Patients ~ 40 - 70 K Hypo - Responsive ESRD patients ~ 366 K ESRD patients on ESA • Estimated cost of at least $ 30 K/year for anemia management • > $ 20 K/year rHuEPO • $ 5 - 10 K/year in transfusion costs Source: USRDS database and primary com
Slide 23: Additional Indications in Renal Anemia
Additional Indications in Renal Anemia • Anemic CKD transplant candidates – Reducing transfusions would prevent increased immunogenicity, shortening “wait - times” and improving transplant outcomes – Estimated US prevalence: ~10,000 patients 2 – Expect to enter Phase 2 trial in 2015, with data in 20
Slide 24: TARGT EPO in Hematological Disorders
TARGT EPO in Hematological Disorders 24
Slide 25: Beta Thalassemia
Beta Thalassemia 25 • Beta Thalassemia is the most common genetic disease worldwide – Yet, it represents an Orphan disorder with significant unmet need • Characteristics in symptomatic patients include 1 : – Severe anemia – Iron overload – Splenomegaly • Patients generally require transfusions and/o
Slide 26: TARGT EPO in Beta Thalassemia Intermedia
TARGT EPO in Beta Thalassemia Intermedia 26 • Clinical Rationale: – eEPO levels are lower than expected in Beta Thalassemia patients ▪ rHuEPO has shown the ability to reduce transfusions and increase hemoglobin levels in Beta Thalassemia patients 1 ▪ Safety concerns have limited usage of rHuEPO – Co
Slide 27: Beta Thalassemia Intermedia Patient Flow
Beta Thalassemia Intermedia Patient Flow 27 ~ 100 , 000 Symptomatic Beta Thalassemia patients W.W. ~ 50,000 Beta Thalassemia Intermedia patients W.W. ~ 15 , 500 Beta Thalassemia Intermedia Patients US/EU • Avg. cost of ~$ 100 K/year* • ~$ 60 K/year in transfusion costs • (> 12 units of blood per yea
Slide 28: Additional Indication in Hematology
Additional Indication in Hematology • Myelodysplastic Syndrome (MDS) – 20 - 55% of MDS patients respond to rHuEPO but use is limited due to safety concerns 1 – Reducing transfusions would limit iron overload – Target population: mild to intermediate patients, EPO levels < 150 – Estimated US prevalen
Slide 29: Additional Pipeline Opportunities
Additional Pipeline Opportunities 29
Slide 30: Novel Peptide Production Capability
Novel Peptide Production Capability • TARGT system has demonstrated the unique ability to produce native peptides in vivo • Native peptides have been difficult to develop into drugs – Short half - life: poor metabolic stability and rapid clearance – Delicate: often require a complex manufacturing pr
Slide 31: Glucagon-like peptide (GLP-2)
Glucagon - like peptide 2 (GLP - 2) • 33 amino acid naturally occurring peptide, t 1 / 2 = 6 - 7 min • Produced by L cells of small intestine • Several important functions: – Increases intestinal absorption – Stimulates intestinal growth – Reduces bone breakdown • Improves intestinal absorption in h
Slide 32: TARGT GLP-2 vs teduglutide
• TARGT GLP - 2 should provide a more favorable PK profile – physiologic levels of continuous GLP - 2 – lower peak dose and continuous coverage • Indications include short bowel syndrome and IBD • Pre - IND meeting in H 1 2015 MDGN TARGT GLP - 2 vs teduglutide 32 Source NPS briefing book, Gattex Adv
Slide 33: MDGN GLP-2 Program
MDGN GLP - 2 Program • We adapted the TARGT platform for expression of peptides < 40 amino acids including GLP - 2 • Program has advanced to in vivo stage in SCID mice (n= 5 ) 33 0 5 10 15 20 25 30 7 18 27 39 49 60 Serum GLP - 2 ng/ml Days from Implantation
Slide 34: Conclusion
Conclusion • Proof of concept established with TARGT ex vivo gene therapy platform as evidenced by the positive initial data of ongoing TARGT EPO clinical trial • Multiple commercially attractive orphan indication s for TARGT EPO identified; data from proof of concept studies expected in H 2 2015 •
Slide 35: Company Development Timeline
Company Development Timeline 35 Long term (2018) ▪ Multiple late - stage clinical programs ▪ First commercial product launch (TARGT EPO ) Mid term ( 2016 - 2017 ) ▪ P ivotal trials for multiple TARGT EPO indications ▪ Proof of concept for GLP - 2 ▪ INDs for 4 early pipeline programs Short term ( 201
Slide 36: Upcoming Catalysts
Upcoming Catalysts 36 TIMING Complete enrollment in MDGN - 201 study Q4 14 Initiate Phase 2 study in Hypo - Responders Q1 15 Initiate Phase 2 study in Anemic CKD Transplant H1 15 Initiate Phase 2 study in Peritoneal Dialysis H1 15 Initiate Phase 2 study in Beta Thalassemia Intermedia H1 15 Initiate
Slide 37: Financial Summary
Financial Summary • NYSE - MKT: MDGN • Shares outstanding – 18.9 M • Warrants and options – 9 M warrants – 7 M options • Cash runway – $ 15 M at September 2014 – Cash burn of ~ $ 1 M per month 37
Slide 38: Appendix
APPENDIX 2 medgenics
Slide 39: Gen 1 System: eEPO Production Drops Off Rapidly
0 5 10 15 20 25 30 -10 0 10 20 30 40 50 60 70 Serum e EPO , mU /ml Days from implantation Gen 1 System: eEPO Production Drops O ff Rapidly • Excellent safety and tolerability profile • One month of erythropoietin production translates into 4 – 5 months of anemia treatment given lifespan of red blood
Slide 40: Patient One - Actively Regulated Reticulocytosis
40 Patient One – Actively Regulated Reticulocytosis (3) TARGT EPO implanted • O ngoing reticulocytosis is evidence of response to eEPO • Repeated peaks and troughs may be indicative of autoregulation • *Possible hemoconcentration * Days from implantation 0 20 40 60 80 100 120 140 Reticulocytes (10 9
Slide 41: TARGT EPO Product Profile - Efficacy
TARGT EPO Product Profile • EFFICACY – Long acting duration of effect ▪ Physiologic levels of eEPO for > 6 months and preferably 1 year – Autologous ▪ Production of all 14 isoforms of eEPO vs one for rHuEPO , mimicking the natural system. This may improve receptor binding and enhance cardio - renal
Slide 42: TARGT EPO Product Profile - Safety
TARGT EPO Product Profile • SAFETY – Elimination of supratherapeutic peaks ▪ High Cmax has been associated with hypertension and serious thromboembolic events* – Reduction in blood pressure vs. injectable rHuEPO • ADMINISTRATION – Simple outpatient procedure – Increase compliance due to implantation
Slide 43: Q3 2014 Results of Operations
Q 3 2014 - Results of Operations 43 • Net R&D expenses for the 3 rd Quarter was $ 2.28 million decreased from $ 2.45 million for the same period in 2013 due to decrease in sub - contractor costs • G&A expenses for the 3 rd Quarter was $ 2.31 million decreasing from $ 2.56 million for the same period